These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30216418)

  • 41. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.
    Sanoff HK; Kim R; Ivanova A; Alistar A; McRee AJ; O'Neil BH
    Invest New Drugs; 2015 Apr; 33(2):505-9. PubMed ID: 25613083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metastatic chordoma with pancreatic disease and response to imatinib.
    Klejnow EV; Hoban K; Nixon I; Elswood TR
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35046072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
    Launay SG; Chetaille B; Medina F; Perrot D; Nazarian S; Guiramand J; Moureau-Zabotto L; Bertucci F
    BMC Cancer; 2011 Oct; 11():423. PubMed ID: 21970335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
    Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
    Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease outcomes for skull base and spinal chordomas: a single center experience.
    Ahmed R; Sheybani A; Menezes AH; Buatti JM; Hitchon PW
    Clin Neurol Neurosurg; 2015 Mar; 130():67-73. PubMed ID: 25590662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
    Liu K; Li G; Fan C; Zhou C; Li J
    Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
    Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
    Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
    Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imatinib mesylate in chordoma.
    Casali PG; Messina A; Stacchiotti S; Tamborini E; Crippa F; Gronchi A; Orlandi R; Ripamonti C; Spreafico C; Bertieri R; Bertulli R; Colecchia M; Fumagalli E; Greco A; Grosso F; Olmi P; Pierotti MA; Pilotti S
    Cancer; 2004 Nov; 101(9):2086-97. PubMed ID: 15372471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
    Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
    Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
    Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
    Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
    Desjardins A; Quinn JA; Vredenburgh JJ; Sathornsumetee S; Friedman AH; Herndon JE; McLendon RE; Provenzale JM; Rich JN; Sampson JH; Gururangan S; Dowell JM; Salvado A; Friedman HS; Reardon DA
    J Neurooncol; 2007 May; 83(1):53-60. PubMed ID: 17245623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
    Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
    Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.
    Zhou J; Sun J; Bai HX; Huang X; Zou Y; Tan X; Zhang Z; Tang X; Tao Y; Xiao B; Zhang PJ; Yang L
    Neurosurgery; 2017 Nov; 81(5):812-823. PubMed ID: 28368502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.